The United States regulators authorised a second booster dose of Pfizer Inc and BioNTech SE’s Covid-19 vaccine for people 50 and older due to concerns about waning immunity in the age group, the drugmakers said on Tuesday.
The U.S. Food and Drug Administration (FDA) also authorised the second booster dose of the vaccine for people aged 12 and older with compromised immune systems.
The new boosters – a fourth round of shots – to be administered at least four months after the third dose are intended to offer more protection against severe disease and hospitalisation, the companies said.
The authorisation comes as some scientists have raised concerns about the highly contagious BA.2 Omicron subvariant, which has driven new spikes in Covid-19 cases in other countries.
Covid-19 cases in the United States have dropped sharply since a record surge in January, but have seen a small uptick over the past week, according to data from the U.S. Centers for Disease Control and Prevention.
“While this EUA (emergency use authorization) will help address a current need for some, we’re working diligently to develop an updated vaccine that not only protects against current Covid-19 strains, but also provides more durable responses,” Pfizer Chief Executive Albert Bourla said in a statement.
Pfizer and BioNTech originally asked for the next booster doses to be authorised for people 65 and older in a submission citing data collected in Israel, where a second booster is already authorised for many people over age 18. The companies did not explain why the age range had been expanded.
Scientists and officials have debated whether young, healthy people will need a fourth shot. A study of Israeli healthcare workers suggested that the fourth dose added little additional protection in the age group.
Biden administration officials have said that the U.S. government currently has enough doses of the vaccines to meet the demand for another round of booster shots in older Americans, even as funding for the U.S. pandemic response has all but run out.
They say that unless Congress approves more spending, the government will likely not to be able to be pay for future inoculations, if they are needed, particularly if the vaccines need to be redesigned to target new variants.
The U.S. Food and Drug Administration (FDA) also authorised the second booster dose of the vaccine for people aged 12 and older with compromised immune systems.
The new boosters – a fourth round of shots – to be administered at least four months after the third dose are intended to offer more protection against severe disease and hospitalisation, the companies said.
The authorisation comes as some scientists have raised concerns about the highly contagious BA.2 Omicron subvariant, which has driven new spikes in Covid-19 cases in other countries.
Covid-19 cases in the United States have dropped sharply since a record surge in January, but have seen a small uptick over the past week, according to data from the U.S. Centers for Disease Control and Prevention.
“While this EUA (emergency use authorization) will help address a current need for some, we’re working diligently to develop an updated vaccine that not only protects against current Covid-19 strains, but also provides more durable responses,” Pfizer Chief Executive Albert Bourla said in a statement.
Pfizer and BioNTech originally asked for the next booster doses to be authorised for people 65 and older in a submission citing data collected in Israel, where a second booster is already authorised for many people over age 18. The companies did not explain why the age range had been expanded.
Scientists and officials have debated whether young, healthy people will need a fourth shot. A study of Israeli healthcare workers suggested that the fourth dose added little additional protection in the age group.
Biden administration officials have said that the U.S. government currently has enough doses of the vaccines to meet the demand for another round of booster shots in older Americans, even as funding for the U.S. pandemic response has all but run out.
They say that unless Congress approves more spending, the government will likely not to be able to be pay for future inoculations, if they are needed, particularly if the vaccines need to be redesigned to target new variants.
For all the latest world News Click Here
Denial of responsibility! TechAI is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
